• Home
  • Study Details
Coming Soon

TReatment of ADC-Refractory Breast CancEr with Dato-DXd or T-DXd: TRADE DXd

The purpose of this study is to test the safety and eff ectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan; or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating your type of cancer. Additional information collected from this study may also help inform the future use of these drugs.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

United States (Nationwide)

Additional Study Information

Principal Investigator

Yara Abdou
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)

IRB Number

24-3069

ClinicalTrials.gov

NCT06533826

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research